Tag: pancreatic cancer

Astellas Pharma and Evopoint Biosciences announced the have entered into an exclusive license agreement for XNW27011, a novel investigational clinical-stage antibody-drug conjugate (ADC) targeting CLDN18.2 (see ADC Drugmap). The agreement grants Astellas a worldwide exclusive license to develop and commercialize XNW27011.

During the upcoming annual meeting of the European Society for Medical Oncology (ESMO), being held in Barcelona, September 13-17, 2024, expect presentations to include new data on advances in the treatment of hard-to-treat cancers using approved and investigational agents, including enfortumab vedotin (Padcev™; Astellas/Pfizer/Seagen), Zolbetuximab (previously known as IMAB362), Enzalutamide (Xtandi®; Astellas/Pfizer) and various pipeline products.

Shanghai-based biopharmaceutical company Antengene, confirmed that ATG-022, a Claudin 18.2 (CLDN18.2) antibody drug conjugate (ADC) being developed by the company, has been granted two Orphan Drug Designations (ODD) consecutively by the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer and pancreatic cancer. 

Cancer-specific plectin (CSP), a pro-tumorigenic protein selectively expressed on the cell surface of major cancers, is a potentially promising target for the development of novel antibody-drug conjugates (ADC).

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to OBI Pharma's OBI-999 for the treatment of Gastric Cancer. Gastric or stomach...

The U.S. Food and Drug Administration (FDA) has accepted the AbGenomics International's Investigational New Drug Application or IND for AbGn-107, the company's antibody-drug conjugate or ADC candidate...

This week, during the World ADC Summit being held October 19 - 22, 2015 in San Diego, CA, Compugen presented the status of its predictive...

To enhance the efficacy of unconjugated antibodies, researchers have optimized their antitumor activity by conjugating them with radionuclides, toxins, or cytotoxic drugs. The choice...